

T-TAS ® 01 (Total Thrombus-formation Analysis System) is placing on the market in the U.S. and Canada.

Fujimori Kogyo Co., Ltd. (Head Office: Shinjuku-ku, Representative Director and President: Eishi Fuyama) has entered into an exclusive distributorship agreement with DiaPharma Group, Inc. (Headquartered in West Chester, Ohio President Madeleine Burmester) for T-TAS ® 01 (Total Thrombus-formation Analysis System) in the U.S. and Canada.

We are planning to launch T-TAS ® 01 in September 2020.

The T-TAS 01 system is the world's first instrument for the quantification of thrombus forming ability of the blood under physiological flow conditions.


T-TAS 01 with PL chip has been cleared by the US Food and Drug Administration (FDA) for the analysis and evaluation of platelet thrombus formation in patients receiving antiplatelet therapy—including aspirin, clopidogrel, prasugrel and ticagrelor—and in patients with primary hemostasis abnormalities such as Glanzmann's thrombasthenia or von Willebrand's Disease.

Together, ZACROS and DiaPharma plan to provide solutions to researchers and clinicians in the fields of thrombosis and hemostasis.

Our company will contribute to the improvement of the quality of medical care in the field of thrombosis and hemostasis by providing this instrument and chips to a wide range of clinical sites, and will also work on the development of medical equipment that can be used with greater peace of mind and comfort by medical professionals.

#### Product Introduction 「T-TAS®01」

- Animated touch panel for easy operation
- Able to 2 specimen simultaneous measurement



Website : T-TAS Special Website

<https://www.t-tas.info/>

Diapharma Group, Inc.

Diapharma Group, Inc. established in 1997, sells hemostasis, thrombosis, platelet function testing, instrumentation, and apoptosis products in the diagnostic and research fields and provides strong technical competence and experience to ensure customer expectations will be met or exceeded.

HP : <https://diapharma.com/company/>

Contact information for this product

Fujimori Kogyo Co., Ltd.

Advanced Medical Business Promotion Department. Business Planning Division.

TEL 03-6381-4228